Showing results (231-240 of 342) with videos related to
Sort By:
Pageof 35
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.Open Forum Infectious Diseases|October 9, 2025
Incidence and Clinical Outcomes of Multiple Viral Infections After Allogeneic Hematopoietic Cell TransplantationKar Yee Yong, Shio Yen Tio, Beatrice Z Sim, et al.International Journal of Molecular Sciences|October 27, 2022
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest RiskMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.Journal of Clinical Medicine|April 14, 2026
Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical StudiesAri Zimran, Jaco Botha, Richard Eastell, et al.Molecular Genetics and Metabolism|December 28, 2010
Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay SachsEtty Osher, Aviva Fattal-Valevski, Liora Sagie, et al.Blood Cells, Molecules & Diseases|June 22, 2014
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Milan Petakov, Pilar Giraldo, et al.Blood Cells, Molecules & Diseases|June 9, 2009
The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)Ari Zimran, Elizabeth Morris, Eugen Mengel, et al.Life (Basel, Switzerland)|June 26, 2025
Prodromal Parkinsonian Features in Carriers of Gaucher Disease Compared to ControlsMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.Pageof 35